| 夏秀娟 李粉婷 刘佳 高欣欣 王新.转移性结直肠癌抗血管生成靶向治疗的研究进展[J].,2016,16(1):187-191 |
| 转移性结直肠癌抗血管生成靶向治疗的研究进展 |
| Anti-angiogenesis Targeted Therapy for Metastatic Colorectal Cancer:Current Situation and Future Perspectives |
| |
| DOI： |
| 中文关键词: 转移性结直肠癌 抗血管生成靶向治疗 贝伐单抗 |
| 英文关键词: Metastatic colorectal cancer (mCRC) Anti-angiogenesis targeted therapy Bevacizumab |
| 基金项目:国家自然科学基金面上项目（81272650；81472701） |
|
| 摘要点击次数: 658 |
| 全文下载次数: 0 |
| 中文摘要: |
| 近年来，由于各种新的化疗药物及分子靶向药物的使用，转移性结直肠癌（metastatic colorectal cancer, mCRC）的个体化治疗
逐步取得了重要的成果。研究表明，抗血管生成靶向药物与化疗药物的联合使用作为转移性结直肠癌的一线治疗方案，可明显改
善治疗效果，延长患者的生存时间。血管内皮生长因子（vascularendothelial growth factor, VEGF）是肿瘤血管生成过程中最主要的
因子。贝伐单抗是通过基因工程技术得到的针对血管内皮生长因子-A（VEGF-A）的单克隆抗体，作为抗血管生成靶向药物用于转
移性结直肠癌的临床治疗。本文对近年来转移性结直肠癌的抗血管生成靶向治疗，尤其是贝伐单抗治疗的相关研究进展进行综
述并展望未来抗血管生成靶向治疗的发展前景。 |
| 英文摘要: |
| In recent years, the treatment of metastatic colorectal cancer (mCRC) has made important progress by means of variable
new chemotherapy and molecular targeted medicine. As first-line treatment for metastatic colorectal cancer, many researches have
showed that the combination of anti-angiogenesis targeted agents and chemotherapy drugs can significantly improve the clinical effects
and prolong the survival time of patients. Vascular endothelial growth factor (VEGF) is the one of the most important factors in the process
of tumor angiogenesis. As the anti-angiogenesis targeted drug for the clinical treatment of metastatic colorectal cancer, bevacizumab
is a monoclonal antibody for vascular endothelial growth factorA (VEGF-A) which is obtained by genetic engineering technique. The
development of anti-angiogenesis targeted therapy for mCRC, particularly bevacizumab, will be reviewed in this article. And the prospect
of future anti-angiogenesis targeted therapy will be discussed. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
